Target intelligence / Profile preview

Anion exchange protein 3 (AE3)

Target
AE3
Molecular classification
Transporter, Solute carrier family, Anion exchanger
01

Overview

Anion exchange protein 3 (AE3) is a member of the solute carrier family 4, encoded by the SLC4A3 gene, and functions as a sodium-independent, electroneutral anion exchanger that mediates bidirectional exchange of chloride (Cl^−) and bicarbonate (HCO₃^−) across the plasma membrane. AE3 is highly expressed in excitable tissues, predominantly brain neurons, heart (cardiac muscle), and retina, where it regulates intracellular pH and bicarbonate homeostasis, thus playing key roles in modulating neuronal excitability and cardiac electrophysiology. Two main isoforms are known: a brain/neuron-predominant form and a cardiac-specific form, generated by alternative splicing. Genetic mutations or disruption of SLC4A3 are causally linked to short QT syndrome type 7—a rare, potentially fatal cardiac arrhythmia—as well as certain forms of epilepsy and retinal degeneration. AE3 activity is uniquely sensitive to inhibition by DIDS, distinguishing it functionally from family members AE1 and AE2. As a disease-associated transporter, AE3 is of research interest for its roles in pathophysiology and potential as a therapeutic target.

Other names
SLC4A3AE3Anion exchange protein 3Anion exchanger 3SLC2CCAE3/BAE3Cardiac/brain band 3-like proteinNeuronal band 3-like proteinSQT7 (refers to disease association, Short QT syndrome 7)Solute carrier family 4 member 3
02

Mechanism of action

Inhibition of chloride-bicarbonate exchange leading to altered pH homeostasis by DIDS and similar anion exchange inhibitors

03

Biological functions

Intracellular pH regulationChloride/bicarbonate exchangeBicarbonate homeostasisModulation of cardiac action potential
04

Disease associations

Cardiovascular disease (especially Short QT syndrome)Epilepsy/Neurodegenerative disease (seizure susceptibility, neuronal excitability)Retinal diseases (e.g., retinitis pigmentosa)
05

Safety considerations

Risk of seizure or cardiac arrhythmia with off-target disturbance or excessive inhibition (due to essential roles in neuronal and cardiac tissue pH regulation)Mutations can result in severe pathologies (sudden cardiac death, epilepsy, retinopathies)
06

Interacting drugs

DIDS (4,4′-Diisothiocyanatostilbene-2,2′-disulfonic acid) (broad inhibitor of anion exchangers)
07

Biomarkers

SLC4A3 mutation as genetic marker in Short QT syndrome and epilepsyLoss-of-function screening for risk of cardiac channelopathies and certain epilepsies

Beyond the preview

Go deeper on Anion exchange protein 3 (AE3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anion exchange protein 3 (AE3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call